Evaluating and Supporting Children and Adolescents Presenting with Post-COVID Conditions

Webinar

View Slides
View Transcript

Overview

Post-COVID conditions (PCC), also referred to as Long COVID or post-acute sequelae of SARS-CoV-2 infection (PASC), is an umbrella term for the wide range of health consequences that are present 4 or more weeks after SARS-CoV-2 infection. Most children infected with SARS-CoV-2 have asymptomatic infection or mild acute symptoms with low rates of hospitalization and death. However, some children and adolescents, including those with mild or asymptomatic infection, develop post-acute manifestations of SARS-CoV-2 infection.

During this COCA Call, presenters will discuss evaluating and supporting post-COVID conditions in children and adolescents and the recommended clinical approach to identifying and managing PCC in children and adolescents based on the "Multi-Disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of PASC in Children and Adolescents" published by the American Academy of Physical Medicine And Rehabilitation (AAPM&R).

Presenters

Tarayn Fairlie, MD, MPH
Medical Officer
Applied Epidemiology Studies Team
Corona and Other Respiratory Viruses Division (CORVD) (proposed)
Centers for Disease Control and Prevention

Louise Vaz, MD, MPH
Associate Professor
Division of Pediatric Infectious Diseases
Oregon Health & Science University

Amanda Morrow, MD
Co-director
Pediatric Post-COVID-19 Rehabilitation Clinic
Kennedy Krieger Institute
Johns Hopkins University School of Medicine
Mt. Washington Pediatric Hospital

Laura Malone, MD, PhD
Co-Director
Pediatric Post-COVID-19 Rehabilitation Clinic
Kennedy Krieger Institute
Johns Hopkins University School of Medicine

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC's role in the topic covered during the presentation.
3. Describe the topic's implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-Specific Objectives:

At the conclusion of the session, the participant will be able to accomplish the following:

1. Describe symptoms and complications in children and adolescents with post-COVID conditions (PCC).
2. Outline AAPM&R Consensus Guidance Statement recommendations to assess children and adolescents with PCC symptoms.
3. Identify appropriate treatments for PCC-related problems in children and adolescents.
4. Highlight accommodations for schools and activities for children and adolescents with PCC.

Continuing Education

To receive continuing education (CE) for WD4520-022323 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Evaluating and Supporting Children and Adolescents Presenting with Post–COVID Conditions, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520-022323. Follow the steps below by March 28, 2025.

1. Register for and complete the course.
2. Pass the post-assessment at 75%.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation.

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-23-004-L04-P and enduring is JA4008229-0000-23-005-H04-P.

Once credit is claimed, an unofficial statement of credit is immediately available on CDC TRAIN. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Laura Malone and Dr. Amanda Morrow's discussion of off label use of medications for managing POTS and chronic headaches, since there are no FDA approved medications for POTS management; they will discuss first line options including beta blockers, fludrocortisone, and midodrine, topiramate, amitriptyline, and cyproheptadine which are approved for other indications.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Fees: No fees are charged for CDC's CE activities.

Target Audience

• Physicians
• Nurses
• Pharmacists
• Veterinarians
• Physician Assistants
• Health Educators
• Other Clinicians

Additional Information

• Contact Information: coca@cdc.gov
• Support/Funding: Centers for Disease Control and Prevention, Emergency Risk Communication Branch
• Method of Participation: You may participate in the educational activity by viewing the program information above.